Target expression details
| Target's General Information | |||||
|---|---|---|---|---|---|
| Target ID | T07400 | ||||
| Target Name | Advanced glycosylation end product receptor (AGER) | ||||
| Synonyms | Receptor foradvanced glycosylation end products; RAGESEC; RAGE; AGER | ||||
| Target Type | Clinical trial | ||||
| Gene Name | AGER | ||||
| Biochemical Class | Immunoglobulin | ||||
| UniProt ID | RAGE_HUMAN | ||||
| Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
| Disease | Alzheimer's disease | ||||
| Example drug | TTP-448 | Phase 2 | [1], [2], [3] | ||
| Tissue | Entorhinal cortex | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 6.77E-03 Z-score: 0.04 P-value: 7.92E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target's Expression Profile across Various Tissues of Healthy Individual | |||||
|
|||||
| References | |||||
| REF 1 | Biopharmaceutical Research Companies are Developing Nearly 100 Medicines for Alzheimer's Disease and Other Dementias. Pharmaceutical Research and Manufacturers of America report. 2012. | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
| REF 3 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.